Acutus Builds On Arrhythmia Mapping Success With New Ablation Devices
The company is supporting two US trials of the AcQBlate Force ablation catheter to support FDA approval of the system to treat atrial flutter and atrial fibrillation.
You may also be interested in...
Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.
The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.
The electrophysiology company announced it will reduce its workforce and take other cost-reduction measures to reduce its annual spending by $23m-$25m. Analysts suspect the company will need to raise more money from investors in 2022 or try to be acquired by a larger company.